The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Piracetam: A Review of Pharmacological Properties and Clinical Uses
Open accessAbstract
Piracetam, a derivative of the neurotransmitter γ‐aminobutyric acid (GABA), has a variety of physiological effects that may result, at least in part, from the restoration of cell membrane fluidity. At a neuronal level, piracetam modulates neurotransmission in a range of transmitter systems (including cholinergic and glutamatergic), has neuroprotective and anticonvulsant properties, and improves neuroplasticity. At a vascular level, it appears to reduce erythrocyte adhesion to vascular endothelium, hinder vasospasm, and facilitate microcirculation. This diverse range of physiological effects is consistent with its use in a range of clinical indications. Its efficacy is documented in cognitive disorders and dementia, vertigo, cortical myoclonus, dyslexia, and sickle cell anemia. While high doses are sometimes necessary, piracetam is well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moncada, S., Gryglewski, R., Bunting, S., & Vane, J. R. (1976) · Nature · doi:10.1038/263663a0 · Cited by 3,595
Terry, A. V., & Buccafusco, J. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041616 · Cited by 1,159
Moncada, S., Higgs, E. A., & Vane, J. R. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91655-5 · Cited by 882
Moncada, S., Herman, A. G., Higgs, E. A., & Vane, J. R. (1977) · Thrombosis Research · doi:10.1016/0049-3848(77)90185-2 · Cited by 680
(1993) · Neuroscience Letters · doi:10.1016/0304-3940(93)90359-s · Cited by 574
Hebbel, R. P., Boogaerts, M. A. B., Eaton, J. W., & Steinberg, M. H. (1980) · New England Journal of Medicine · doi:10.1056/nejm198005013021803 · Cited by 518
Committee for Proprietary Medicinal Products (CPMP)
Nahler, G. (2009) · Dictionary of Pharmaceutical Medicine · doi:10.1007/978-3-211-89836-9_243 · Cited by 441
Glutamatergic neurotransmission in aging: a critical perspective
Segovia, G., Porras, A., Del Arco, A., & Mora, F. (2001) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(00)00225-6 · Cited by 377
What cognitive changes can be expected with normal ageing?
Christensen, H. (2001) · Australian & New Zealand Journal of Psychiatry · doi:10.1046/j.1440-1614.2001.00966.x · Cited by 321
Singer, T., Verhaeghen, P., Ghisletta, P., Lindenberger, U., & Baltes, P. B. (2003) · Psychology and Aging · doi:10.1037/0882-7974.18.2.318 · Cited by 289
Cited by
Novel psychoactive substances of interest for psychiatry
Schifano, F., Orsolini, L., Duccio Papanti, G., & Corkery, J. M. (2015) · World Psychiatry · doi:10.1002/wps.20174 · Cited by 321
Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review
Battleday, R. M., & Brem, A.-K. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.07.028 · Cited by 215
Klitgaard, H., Matagne, A., Nicolas, J., Gillard, M., Lamberty, Y., De Ryck, M., Kaminski, R. M., Leclercq, K., Niespodziany, I., Wolff, C., et al. (2016) · Epilepsia · doi:10.1111/epi.13340 · Cited by 168
Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities
Rueda, N., Flórez, J., & Martínez-Cué, C. (2012) · Neural Plasticity · doi:10.1155/2012/584071 · Cited by 171
Glutamate receptor dysfunction and drug targets across models of autism spectrum disorders
Carlson, G. C. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.02.003 · Cited by 102
Metadata
- Authors
- Winblad, B.
- Venue
- CNS Drug Reviews
- Publisher
- Wiley
- Published
- 2005-03
- Volume
- 11
- Issue
- 2
- Pages
- 169-182
- ISSN
- 1080-563X (ISSN-L)
- 1527-3458
- OpenAlex
- W2033989135
- Cited by
- 317
- References
- 53
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Piracetam: A Review of Pharmacological Properties and Clinical Uses. https://app.cochat.ai/papers/10.1111/j.1527-3458.2005.tb00268.x
- The paper
- Winblad, B. (2005). Piracetam: A Review of Pharmacological Properties and Clinical Uses. CNS Drug Reviews. https://doi.org/10.1111/j.1527-3458.2005.tb00268.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.